Quantum Biopharma (QNTM) Total Current Liabilities (2018 - 2026)

Quantum Biopharma (QNTM) has 9 years of Total Current Liabilities data on file, last reported at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 58.02% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 58.02% YoY), and the FY2025 full-year result was $6.1 million, down 9.29% from the prior year.
• Total Current Liabilities advanced to $16.3 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $16.3 million in Q1 2026 to a low of $4.6 million in Q4 2023.
• A 5-year average of $8.5 million and a median of $6.7 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 41.69% in 2023 and jumped 162.64% in 2025, its largest moves.
• Tracing QNTM's Total Current Liabilities over 5 years: stood at $7.8 million in 2022, then plunged by 41.69% to $4.6 million in 2023, then surged by 46.29% to $6.7 million in 2024, then retreated by 9.29% to $6.1 million in 2025, then surged by 169.81% to $16.3 million in 2026.
• Business Quant data shows QNTM's Total Current Liabilities at $16.3 million in Q1 2026, $6.1 million in Q4 2025, and $6.6 million in Q3 2025.